Citations

Clear

16280 citation(s) found for "Yu, David".

Complication of Minimally Invasive Radical Cystectomy
Giedelman, Camilo , Sotelo, René , Castle, Erik P., Castillo, Octavio , Canes, David , Andrade, Robert De, Spinelli, Matteo Giulio , Carmona, Oswaldo, Saavedra, José M.

Mayo Clinic

Videourology™ | February 2, 2012 | Volume: 26 | Issue: 1 | Pages: No page available

10.1089/vid.2011.0030 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2011.0030.M1 sj-vid-1-vid-10.1089_vid.2011.0030
Cutting Edge: Regulation of TLR4-Driven B Cell Proliferation by RP105 Is Not B Cell Autonomous
Flick, Leah M., Divanovic, Senad , Jackson, Shaun W. , Bram, Richard J. , Rawlings, David J. , Finkelman, Fred D. , Karp, Christopher L. , Allen, Jessica L.

Mayo Clinic

The Journal of Immunology | January 31, 2012 | Volume: 188 | Issue: 5 | Pages: 2065-2069

10.4049/jimmunol.1103282 | PMID 22291190 Get It

Abstract Mechanistic understanding of RP105 has been confounded by the fact that this TLR homolog has appeared to have opposing, cell type-specific effects on TLR4 signaling. Although RP105 inhibits TLR4-driven signaling in cell lines and myeloid cells, impaired LPS-driven proliferation by B cells from RP105−/− mice has suggested that RP105 facilitates TLR4 signaling in B cells. In this article, we show that modulation of B cell proliferation by RP105 is not a function of B cell-intrinsic expression of RP105, and identify a mechanistic role for dysregulated BAFF expression in the proliferative abnormalities of B cells from RP105−/− mice: serum BAFF levels are elevated in RP105−/− mice, and partial BAFF neutralization rescues aberrant B cell proliferative responses in such mice. These data indicate that RP105 does not have dichotomous effects on TLR4 signaling and emphasize the need for caution in interpreting the results of global genetic deletion.
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Pasquinelli, C, McPhee, Fiona, Eley, Timothy, Villegas, Criselda, Sandy, Katrina, Sheridan, Pamela L., Persson, Anna , Huang, Shu-Pang, Hernandez, Dennis , Sheaffer, Amy K. , Scola, Paul M. , Marbury, Thomas , Goldwater, Ronald, Rodríguez‐Torres, M., DeMicco, Michael, Wright, David W. , Kraft, Walter K. , Lopez-Talavera, Juan-Carlos, Grasela, Dennis M., Lawitz, Eric , Charlton, Michael

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 31, 2012 | Volume: 56 | Issue: 4 | Pages: 1838-1844

10.1128/aac.05854-11 | PMID 22290978 Get It

ABSTRACT Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.
Quality of Life Improvement with Sublingual Immunotherapy: A Prospective Study of Efficacy
Morris, Mary S., Lowery, Amanda, Theodoropoulos, Demetrios S., Duquette, R. Daniel, Morris, David L.

Mayo Clinic

Journal of Allergy | January 30, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/253879 | PMID 22500181 Get It

Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10–12 months of SLIT. Significant improvement () on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.
Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation
Carey, Elizabeth J. , Aqel, Bashar , Byrne, Thomas , Douglas, David D., Rakela, Jorge , Vargas, Hugo E. , Moss, Adyr A. , Reddy, Kunam S. , Chakkera, Harini A. , Aqel, Bashar A. , Mulligan, David C. , Vargas, Hugo E , Chakkera, Harini A

Mayo Clinic

Journal of Transplantation | January 29, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/614781 | PMID 22461975 Get It

New-onset diabetes after transplantation (NODAT) is common after liver transplant and associated with poorer outcomes. The aim of this study was to identify risk factors for NODAT in liver transplant recipients off corticosteroids. In 225 adult nondiabetic liver transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation, 17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were significant. Each 10 mg/dL increase in pretransplant FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in patients off corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.
Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy
Park, Soon J., Milano, Carmelo A. , Tatooles, Antone, Rogers, Joseph G. , Adamson, Robert, Steidley, D. Eric , Ewald, Gregory A. , Sundareswaran, Kartik S., Farrar, David J. , Slaughter, Mark S.

Mayo Clinic

Circulation: Heart Failure | January 27, 2012 | Volume: 5 | Issue: 2 | Pages: 241-248

10.1161/circheartfailure.111.963991 | PMID 22282104 Get It

Background— The HeartMate II (HMII) destination therapy (DT) trial demonstrated significant improvements in outcomes in continuous-flow left ventricular assist devices compared with patients implanted with the pulsatile-flow HeartMate XVE. The primary hypothesis of the current study is that trial patients enrolled after the initial data cohort would have better clinical outcomes. Methods and Results— Two hundred eighty-one patients who underwent HMII for DT from May 2007 to March 2009 (Mid Trial [MT] group) were compared with the initial 133 HMII patients from March 2005 to May 2007 (Early Trial [ET] group). Patient entry criteria were the same during the 2 time periods. Survival, adverse events, and quality of life were compared between the 2 groups. Baseline characteristics were similar between the groups. Compared with the ET group, patients in the MT group had reduced adverse event rates for bleeding requiring transfusions (1.66 versus 1.13 events per patient-year, P <0.001), sepsis (0.38 versus 0.27, P =0.025), device-related infections (0.47 versus 0.27, P <0.001), and hemorrhagic stroke (0.07 versus 0.03, P =0.01). Other event rates were similar between groups including ischemic stroke (0.06 versus 0.05 events per patient-year, P =0.57). Survival at 1 year in the MT group was 73% versus 68% in the ET group ( P =0.21). Additionally, there was a significant reduction in deaths caused by hemorrhagic stroke ( P =0.01). Quality of life improvements were significant in both the groups ( P <0.001). Conclusions— The benefit of DT therapy with the HMII is confirmed in subsequent trial patients, with improved adverse event rates and a strong trend for improvements in survival. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00121485.
The incidence of MCI differs by subtype and is higher in men
Roberts, Rosebud O., Geda, Yonas E. , Cha, R.H., Tangalos, Eric G., Ivnik, Robert J., Rocca, Walter A. , Petersen, Ronald C. , Knopman, David S. , Pankratz, V. Shane , Boeve, Bradley F. , Geda, Yonas E

Mayo Clinic

Neurology | January 26, 2012 | Volume: 78 | Issue: 5 | Pages: 342-351

10.1212/wnl.0b013e3182452862 | PMID 22282647 Get It

Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants
White, Kristin L., Schildkraut, Joellen M. , Palmieri, Rachel T., Iversen, Edwin S., Vierkant, Robert A. , Rider, David N., Charbonneau, Bridget, Cicek, Mine S., Sutphen, Rebecca , Birrer, Michael J. , Song, Honglin , Gayther, Simon A. , Ramus, Susan J. , Wentzensen, Nicolas , García‐Closas, Montserrat , Phelan, Catherine M., Cunningham, Julie M. , Sellers, Thomas A. , Goode, Ellen L. , Weber, Rachel Palmieri , Berchuck, Andrew , Pharoah, Paul D.P. , Tyrer, Jonathan P. , Yang, Hannah , Fridley, Brooke L. , Ramus, Susan J , Vierkant, Robert A , García-Closas, Montserrat

Mayo Clinic

Cancer Research | January 26, 2012 | Volume: 72 | Issue: 5 | Pages: 1064-1069

10.1158/0008-5472.can-11-3512 | PMID 22282663 Get It

Abstract The importance of inflammation pathways to the development of many human cancers prompted us to examine the associations between single-nucleotide polymorphisms (SNP) in inflammation-related genes and risk of ovarian cancer. In a multisite case–control study, we genotyped SNPs in a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using a custom array and analyzed by logistic regression. SNPs with P &lt; 0.10 were evaluated among 3,143 cases and 2,102 controls from the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) post-GWAS collaboration. Combined analysis revealed association with SNPs rs17561 and rs4848300 in the interleukin gene IL1A which varied by histologic subtype (Pheterogeneity = 0.03). For example, IL1A rs17561, which correlates with numerous inflammatory phenotypes, was associated with decreased risk of clear cell, mucinous, and endometrioid subtype, but not with the most common serous subtype. Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated with decreased risk. Thus, inherited variation in IL1A and ALOX5 seems to affect ovarian cancer risk which, for IL1A, is limited to rarer subtypes. Given the importance of inflammation in tumorigenesis and growing evidence of subtype-specific features in ovarian cancer, functional investigations will be important to help clarify the importance of inherited variation related to inflammation in ovarian carcinogenesis. Cancer Res; 72(5); 1064–9. ©2012 AACR.
The Natural History of Preclinical Diastolic Dysfunction
Vogel, Mark W., Slusser, Joshua P. , Hodge, David O. , Chen, Horng H.

Mayo Clinic

Circulation: Heart Failure | January 26, 2012 | Volume: 5 | Issue: 2 | Pages: 144-151

10.1161/circheartfailure.110.959668 | PMID 22278404 Get It

Background— Preclinical diastolic dysfunction (PDD) has been broadly defined as subjects with left ventricular diastolic dysfunction, without the diagnosis of congestive heart failure (HF) and with normal systolic function. Our objective was to determine the risk factors associated with the progression from PDD (stage B) HF to symptomatic (stage C) HF. Methods and Results— Using the resources of the Rochester Epidemiology Project, all residents of Olmsted County, MN, who underwent echocardiography between January 1, 2004, and December 31, 2005, and had grade 2–4 diastolic dysfunction and ejection fraction ≥50% were identified. Patients with a diagnosis of HF before or within 30 days of the echocardiogram were excluded. Patients were also excluded if they had a diagnosis of atrial fibrillation or severe mitral or aortic valve regurgitation at the time of the echocardiogram. A total of 388 patients met the inclusion criteria. The mean age of the cohort was 67±12 years, with a female (57%) predominance. Prevalence of renal insufficiency (estimated glomerular filtration rate <60 mL/min per 1.73 m 2 ) was 34%. The 3-year cumulative probabilities of development of (stage C) HF, development of atrial fibrillation, cardiac hospitalization, and mortality were 11.6%, 14.5%, 17.7%, and 10.1% respectively. In multivariable Cox proportional hazard regression analysis, we determined that age, renal dysfunction, and right ventricular systolic pressure were independently associated with the development of HF. Conclusions— This population-based study demonstrated that in PDD (stage B) HF, there was a moderate degree of progression to symptomatic (stage C) HF over 3 years, and renal dysfunction was associated with this progression independent of age, sex, hypertension, coronary disease, and ejection fraction.
Role of Protein Kinase D in Golgi Exit and Lysosomal Targeting of the Transmembrane Protein, Mcoln1
Marks, David L. , Holicky, Eileen L., Wheatley, Christine L., Frumkin, Ayala , Bach, Gideon , Pagano, Richard E.

Mayo Clinic

Traffic | January 23, 2012 | Volume: 13 | Issue: 4 | Pages: 565-575

10.1111/j.1600-0854.2012.01331.x | PMID 22268962 Get It

The targeting of lysosomal transmembrane (TM) proteins from the Golgi apparatus to lysosomes is a complex process that is only beginning to be understood. Here, the lysosomal targeting of mucolipin‐1 (Mcoln1), the TM protein defective in the autosomal recessive disease, mucolipidosis type IV, was studied by overexpressing full‐length and truncated forms of the protein in human cells, followed by detection using immunofluorescence and immunoblotting. We demonstrated that a 53‐amino acid C‐terminal region of Mcoln1 is required for efficient exit from the Golgi. Truncations lacking this region exhibited reduced delivery to lysosomes and decreased proteolytic cleavage of Mcoln1 into characteristic ∼35‐kDa fragments, suggesting that this cleavage occurs in lysosomes. In addition, we found that the co‐expression of full‐length Mcoln1 with kinase‐inactive protein kinase D (PKD) 1 or 2 inhibited Mcoln1 Golgi exit and transport to lysosomes and decreased Mcoln1 cleavage. These studies suggest that PKDs play a role in the delivery of some lysosomal resident TM proteins from the Golgi to the lysosomes.